CN115353554A - Active peptide for stimulating pancreatic hyperglycemia peptide-1 secretion and preparation method and application thereof - Google Patents
Active peptide for stimulating pancreatic hyperglycemia peptide-1 secretion and preparation method and application thereof Download PDFInfo
- Publication number
- CN115353554A CN115353554A CN202210735399.2A CN202210735399A CN115353554A CN 115353554 A CN115353554 A CN 115353554A CN 202210735399 A CN202210735399 A CN 202210735399A CN 115353554 A CN115353554 A CN 115353554A
- Authority
- CN
- China
- Prior art keywords
- secretion
- peptide
- active peptide
- glucagon
- stimulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 80
- 230000028327 secretion Effects 0.000 title claims abstract description 65
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 title abstract description 8
- 101710176384 Peptide 1 Proteins 0.000 title abstract description 8
- 201000001421 hyperglycemia Diseases 0.000 title abstract description 8
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 59
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 230000006870 function Effects 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 9
- 235000000346 sugar Nutrition 0.000 claims abstract description 7
- 241000209219 Hordeum Species 0.000 claims description 58
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 39
- 102100040918 Pro-glucagon Human genes 0.000 claims description 39
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 35
- 239000000047 product Substances 0.000 claims description 22
- 101710173663 Glucagon-1 Proteins 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 102000057297 Pepsin A Human genes 0.000 claims description 9
- 108090000284 Pepsin A Proteins 0.000 claims description 9
- 102000004142 Trypsin Human genes 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 9
- 239000000413 hydrolysate Substances 0.000 claims description 9
- 229940111202 pepsin Drugs 0.000 claims description 9
- 239000012588 trypsin Substances 0.000 claims description 9
- 230000002255 enzymatic effect Effects 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 210000003158 enteroendocrine cell Anatomy 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000751 protein extraction Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 230000007717 exclusion Effects 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 4
- 235000013305 food Nutrition 0.000 abstract description 12
- 230000002496 gastric effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- 102000038379 digestive enzymes Human genes 0.000 abstract description 2
- 108091007734 digestive enzymes Proteins 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 240000005979 Hordeum vulgare Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 21
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 13
- 101710142157 Stanniocalcin-1 Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 230000000975 bioactive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000010587 phase diagram Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention relates to an active peptide for stimulating the secretion of pancreatic hyperglycemia peptide-1, a preparation method and application thereof. The active peptide for stimulating the secretion of the pancreatic hyperglycemia peptide-1 is VVTTGVGGQ, and the amino acid sequence is as follows: val-Val-Thr-Gly-Val-Gly-Gly-Gln. The active peptide has a novel structure, can be obtained by separating and purifying the enzymolysis barley protein, and can also be artificially synthesized by adopting a chemical solid-phase synthesis method. The VVTGVGGQ peptide has the function of stimulating the secretion of glucagon-like peptide-1 (GLP-1), has the characteristics of strong activity, safety, no toxic or side effect, simple preparation, convenient industrial production, difficult degradation by gastrointestinal digestive enzymes and easy absorption, and can be used as an important functional component or food base material for preparing foods, health-care foods and medicines with the functions of preventing diabetes or assisting in reducing blood sugar.
Description
Technical Field
The invention belongs to the field of bioactive peptides, and particularly relates to a bioactive peptide for stimulating pancreatic hyperglycemia peptide-1 secretion, and a preparation method and application thereof.
Background
Diabetes mellitus (diabetes) is a disease of endocrine metabolism associated with defective insulin secretion or impaired biological action thereof, characterized primarily by hyperglycemia. The long-standing hyperglycemia results in chronic damage and dysfunction of various tissues, particularly the eye, kidney, heart, blood vessels, nerves. The diabetes mainly comprises type I diabetes and type II diabetes, and the type II diabetes is the main diabetes in Chinese diabetes population, and accounts for more than 90 percent of the total number of diabetes patients. Type II diabetes is a slowly progressive disease whose central elements in the pathogenesis are insulin resistance and defects in islet beta cell function. In view of the large number of patients with type II diabetes and the serious harmfulness thereof, preventive and therapeutic measures for developing type II diabetes are not slow. Currently, many drugs including sulfonylureas, biguanides, hypoglycemic agents, alpha glucosidase inhibitors, insulin sensitizers, etc. are used for the treatment of type II diabetes. These antidiabetic drugs, although having a definite therapeutic effect, are expensive and prone to cause many side effects and drug resistance. Therefore, the development of functional food or health food with low price, small side effect and diabetes improving activity is of great significance.
Glucagon-like peptide-1 (glp-1) is a gastrointestinal hormone secreted by the endocrine L cells of the small intestine of humans that helps the body produce a postprandial insulin response after eating carbohydrates. GLP-1 has important application value in the treatment process of type II diabetes. GLP-1 has physiological functions of stimulating insulin secretion, promoting islet beta cell proliferation and inhibiting apoptosis, inhibiting postprandial glucagon secretion, reducing glycogen synthesis, improving insulin sensitivity, and controlling appetite. Thus, GLP-1 has become a hotspot for research on new strategies for the prevention and treatment of diabetes. Increasing the secretion of GLP-1 from the intestinal tract is of great importance for the prevention and treatment of type II diabetes. Studies have demonstrated that GLP-1 secretion is regulated by dietary factors. Therefore, the secretion of GLP-1 in the intestinal tract can be regulated through diet so as to improve or prevent the II diabetes.
Food-derived bioactive peptides are a common dietary factor. As a hydrolysate of food protein, the food-derived bioactive peptide has the characteristics of easy digestion and absorption by human bodies, high edible safety and the like. The development of the food-derived bioactive peptide industry is highly regarded by the country, and it is clearly pointed out that the development of functional foods is accelerated, the development of health-care and health-care foods such as bioactive peptides is supported, and application demonstration is developed. Currently, the sources of food-derived bioactive peptides mainly include animal proteins and plant proteins, and plant proteins are receiving more and more attention due to environmental, economic, sustainability and other factors. Barley is the fourth crop of grain worldwide, second only to wheat, rice and corn, with annual global barley yields of over 1 million tons. The barley protein has rich source and low price, mainly comes from byproducts of barley starch processing and beer production, but cannot be fully utilized. Therefore, the method has important economic value and social significance for developing bioactive peptide products by utilizing the barley protein and further preventing and relieving the diabetes.
Disclosure of Invention
The invention aims to provide an active peptide for stimulating the secretion of glucagon-1 peptide, a preparation method and application thereof.
The purpose of the invention can be realized by the following technical scheme:
in a first aspect of the invention, an active peptide for stimulating the secretion of glucagon-1 is provided, the active peptide is VVTTGVGGQ, and the amino acid sequence is as follows: val-Val-Thr-Gly-Val-Gly-Gly-Gln.
Preferably, the active peptide for stimulating the secretion of glucagon-1 is derived from barley protein.
The active peptide provided by the invention is derived from barley protein, has the function of stimulating the secretion of glucagon-like peptide-1 (GLP-1), has the characteristics of strong activity, safety, no toxic or side effect, simple preparation, convenient industrial production, difficult degradation by gastrointestinal digestive enzymes and easy absorption, and can be used as an important functional component or food base material for preparing foods, health-care foods and medicines with the functions of preventing diabetes or assisting in reducing blood sugar.
In a second aspect of the present invention, there is provided a polynucleotide encoding said active peptide that stimulates secretion of glucagon-1 peptide.
In a third aspect, the invention provides a preparation method of the active peptide for stimulating the secretion of the pancreatic hyperglycemia peptide-1, wherein the active peptide is artificially synthesized by a genetic engineering method, or is directly obtained from the barley protein by a separation and purification method, or is directly prepared by chemical synthesis.
The artificial synthesis of the active peptide for stimulating the secretion of glucagon-1 peptide by genetic engineering methods is a technical solution which can be realized by the skilled person, and for example, the sequence synthesis of the polypeptide can be controlled by a suitable DNA template based on DNA recombination technology.
The way for directly obtaining the barley protein by a separation and purification method can be as follows: based on the given amino acid sequence of the active peptide for stimulating the secretion of the pancreatic hyperglycemic peptide-1, the active peptide for stimulating the secretion of the pancreatic hyperglycemic peptide-1 is obtained from barley by adopting a conventional enzymolysis, separation and purification method in the biological technology.
The preparation method by chemical synthesis is to synthesize the active peptide for stimulating the secretion of the glucagon-1 by adopting a traditional solid phase synthesis method.
In a fourth aspect of the present invention, there is provided a method for preparing an enzymatic hydrolysate containing the active peptide that stimulates the secretion of glucagon-1, wherein a two-step enzymatic hydrolysis method is used to carry out enzymatic hydrolysis on barley protein, comprising the steps of: and sequentially carrying out enzymolysis on the barley protein by using pepsin and trypsin to obtain a barley protein enzymolysis product, namely an enzymolysis product containing the active peptide for stimulating the secretion of the glucagon-1.
In one embodiment of the present invention, the method for sequentially hydrolyzing barley protein with pepsin and trypsin comprises the following steps:
1) Extracting barley protein from barley;
2) Carrying out enzymolysis on the barley protein by using the pepsin to obtain a first enzymolysis product;
3) And (3) carrying out enzymolysis on the first enzymolysis product by using the trypsin to obtain a barley protein enzymolysis product.
In one embodiment of the present invention, the method for extracting barley protein from barley comprises the steps of:
grinding barley, defatting, adding into distilled water, adjusting pH to 4-6, and pretreating with cellulase for 0.5-2 hr; then adjusting pH to 10-12 for protein extraction, centrifuging after finishing, taking supernatant, adjusting pH of the supernatant to 4.4-4.6, standing, centrifuging, and washing with water; and finally drying to obtain the barley protein.
In one embodiment of the present invention, the mass ratio of the pepsin or trypsin to the barley protein is 1:10-100.
In one embodiment of the invention, the enzymolysis condition of the pepsin or trypsin is enzymolysis at 37 ℃ for 1-5h.
In one embodiment of the present invention, after obtaining the barley protein enzymolysis product in step 3), the method further comprises the following steps:
separating the barley protein enzymolysis product by using a Toyopearl HW-40F size exclusion chromatographic column, eluting and carrying out chromatographic purification at a certain flow rate by using deionized water as an eluent, and collecting different components; then detecting the influence of different components on the secretion of GLP-1 of enteroendocrine cells, selecting the component which stimulates the GLP-1 to secrete the highest activity as a target component, namely an enzymolysis product containing the active peptide which stimulates the secretion of the glucagon-like peptide-1.
In the fifth aspect of the present invention, an enzymatic hydrolysate containing the active peptide for stimulating the secretion of glucagon-1, prepared based on the above preparation method, is provided.
The sixth aspect of the present invention provides an application of the active peptide for stimulating glucagon-peptide-1 secretion and an enzymatic hydrolysate containing the active peptide for stimulating glucagon-peptide-1 secretion in the preparation of a product having at least one function of the following 1) -3):
1) Stimulation of GLP-1 secretion;
2) Preventing diabetes;
3) Assisting in reducing blood sugar.
In a seventh aspect of the present invention, a product is provided, wherein the product comprises the active peptide for stimulating the secretion of glucagon-1, or comprises an enzymatic hydrolysis product of the active peptide for stimulating the secretion of glucagon-1, and the product has at least one of the following functions 1) to 3):
1) Stimulation of GLP-1 secretion;
2) Preventing diabetes;
3) And (5) assisting in reducing blood sugar.
The product includes food, functional food/health food and medicine.
Compared with the prior art, the invention has the advantages and beneficial effects that:
on the basis of a great deal of previous work of the applicant, the active peptide with the function of stimulating the secretion of GLP-1 in the intestinal tract is screened out, and the sequence of the active peptide is novel and has no relevant report; the active peptide can be prepared from food protein barley protein, so that the active peptide has the advantages of safety and no toxic or side effect; the molecular weight of the VVTGVGGQ active peptide is below 1000Da, the molecular weight is small, and the VVTGVGGQ active peptide not only can stimulate GLP-1 secretion of an intestinal tract, but also can be easily absorbed by an organism, so that the VVTGVGGQ active peptide has a good nutritional function; the preparation method of the active peptide containing the VVTTGVGGQ sequence is simple, easy to operate, convenient for industrial large-scale production and has important application value.
Drawings
FIG. 1 is a liquid phase diagram and a mass spectrogram of a VVTTGVGGQ sequence active peptide after artificial synthesis;
FIG. 2 is a graph of the effect of VVTGGVGGQ on GLP-1 secretion by STC-1 cells;
FIG. 3 is a graph showing the effect of different concentrations of barley protein zymolyte on GLP-1 secretion by STC-1 cells;
FIG. 4 is a graph showing the effect of barley protein zymolyte on GLP-1 secretion by mouse enteroendocrine cells;
FIG. 5 is a graph of a barley protein hydrolysate fractionated with a HW-40F size exclusion chromatography column;
FIG. 6 is a graph of the effect of isolated fractions on GLP-1 secretion by STC-1 cells;
FIG. 7 is a MS/MS map of the active peptide of VVTGGVGGQ sequence in the isolated fraction F1.
Detailed Description
The invention is described in detail below with reference to the figures and the specific embodiments.
Example 1 Artificial Synthesis and Activity evaluation of VVTTGVGGQ sequence active peptides
1. Synthesis of VVTGGVGGQ sequence active peptide
The VVT VGGQ active peptide is synthesized by a peptide solid phase synthesis method from Zhejiang Hongtuo science and technology Limited, the purity of the synthesized peptide is more than 95 percent verified by a high performance liquid phase method and a mass spectrum technology, and a liquid phase diagram and a mass spectrum diagram of the active peptide are shown in 1.
2. Influence of VVTTGVGGQ sequence active peptide on GLP-1 secretion of SCT-1 cells
(1) Culture of STC-1 cells
STC-1 cells were cultured in DMEM medium containing 10% Fetal Bovine Serum (FBS), 1% nonessential amino acids (NEAA), 100U/mL penicillin and 0.1mg/mL streptomycin. Cells were incubated at 37 ℃ with 5% CO 2 And when 80-90% density is reached, subculture is performed by trypsinization.
(2) Determination of STC-1 cell secretion hormone content
The active peptide was prepared in 2mM molar peptide solution using Hank's buffer. STC-1 cells were plated at 1.25X 10 in 24-well plates 5 Density seeding of individual cells. When the cells reached 80-90% confluence, the cells were washed twice with Hank's buffer to remove the media. The active peptide solution was added to STC-1 cells and the cells were incubated for 2h at 37 ℃ in an incubator. After the incubation was completed, the cells were centrifuged at 1000g for 20min to obtain the supernatant. The GLP-1 content is determined by a commercial GLP-1 kit of Wuhanyun clone science and technology GmbH.
The effect of active peptides on GLP-1 secretion by STC-1 cells is shown in FIG. 2, and it can be seen that all the active peptides can significantly stimulate GLP-1 secretion by STC-1 cells. A great deal of research currently proves that GLP-1 has physiological functions of stimulating the secretion of insulin, proliferating and inhibiting the apoptosis of islet beta cells, inhibiting the secretion of glucagon after meals, reducing the synthesis of glycogen, improving the sensitivity of insulin and controlling appetite. The VVTTGVGGQ active peptide can stimulate GLP-1 secretion at present, and therefore, the peptide has important application value for preventing diabetes or assisting in reducing blood sugar.
Example 2 preparation of barley protein zymolyte and Activity evaluation
(1) Preparation of barley protein zymolyte
Barley was milled through an 80 mesh screen and then defatted with hexane. The defatted barley flour was soaked in distilled water at a mass ratio of 12. Then the pH value is adjusted to 11.0 by 1mol/L NaOH, and after 2 hours of action of a magnetic stirrer, the supernatant is obtained by centrifugation. Adjusting the pH value of the supernatant to the isoelectric point (pH 4.5) with 1mol/L HCl, standing for 1h, centrifuging, washing the precipitate with water to neutrality, redissolving with a small amount of distilled water, freeze-drying to obtain barley protein, and storing at 4 deg.C for use.
Lyophilized protein powder 1g was dissolved in 20mL of K containing 25mg of freshly prepared pepsin 2 HPO 4 -KH 2 PO 4 The pH of the solution was adjusted to 2.0 with HCl (1 mol/L) in phosphate buffer (0.1 mol/L) and incubated at 37 ℃ for 2h. After the incubation is finished, the pH value of the solution is adjusted to 6.8 by NaOH (1 mol/L), and then 50mg of trypsin is added for continuous enzymolysis for 2h. And (4) inactivating the enzyme for 8min in a boiling water bath, centrifuging, taking the supernatant, and freeze-drying to obtain the barley protein zymolyte.
(2) Activity evaluation
Barley protein zymolyte is prepared into solutions with the mass concentration of 3,4,5mg/mL by Hank's buffer solution, and the influence of the zymolyte on GLP-1 secretion of STC-1 cells is measured by the method, and the result is shown in figure 3. From the results, it can be seen that the barley protein zymolyte can significantly stimulate GLP-1 secretion from STC-1 cells.
In addition, the effect of barley protein hydrolysate on the secretion of hormones by enteroendocrine cells of mice was evaluated at the animal level. After 1 week of acclimation period, ICR mice were randomized into 2 groups (28 per group). Control group: normal saline for gastric perfusion; barley proteolytic group: gavage barley protein hydrolysate (1.0 g/kg body weight). After gastric lavage, the eyes were removed at 0, 15min,30min,60min,90min,120min, and 150min, respectively, and blood was collected, and placed in a centrifuge tube containing EDTA (final concentration of 1 mg/mL) and aprotinin (final concentration of 0.6 TIU/mL), and the supernatant was centrifuged to obtain the supernatant, and the GLP-1 hormone content in the serum was measured by ELISA. GLP-1 in the serum of the gavage normal saline group is maintained at about 45pg/mL during the period. The results of the group of barley protein zymolytes after gastric lavage are shown in FIG. 4, it can be found that the barley protein zymolytes increase the GLP-1 level in the mouse, and at 30min, the barley protein zymolytes have the largest influence on the secretion of GLP-1 by enteroendocrine cells of the mouse, and the GLP-1 concentration in the blood can be increased by about 120pg/mL, and can be increased by 2.7 times.
EXAMPLE 3 preparation of active peptides that promote GLP-1 secretion by barley protein
Taking a Toyopearl HW-40F filler, conventionally swelling and packing the filler (filling buffer solution is 0.1M NaCl dissolved in 50mM phosphate), wherein the height of the column is 10cm, the inner diameter of the column is 2.6cm, a water layer needs to be reserved at the top of the column at any moment for 1.5-2cm, the column can be used after about 3-4 column volumes are balanced, and the barley protein zymolyte is loaded when the liquid level is reserved for 2-3 mM. Weighing barley protein zymolyte powder about 20mg, dissolving in 2mL of distilled water, filtering with 0.45 μm microporous membrane, adding into chromatographic column, eluting with distilled water at an elution speed of 2mL/min, and collecting the elution peak. The barley protein zymolyte separation pattern is shown in FIG. 5, and it can be seen that the HW-40F chromatographic column divides the protein zymolyte into 4 peptide fractions.
The 4 peptide fractions were subjected to activity evaluation by the above-described method, and the results are shown in FIG. 6. Of the 4 peptide fractions, the F1 fraction was found to have the best ability to stimulate GLP-1 secretion from STC-1 cells. Thus, the F1 component is a highly active GLP-1 secretion promoting active peptide.
Example 4 identification of barley protein VVTTGVGGQ sequence active peptides
Peptide sequences in the F1 fraction were identified using mass spectrometry techniques. The sample was dissolved in distilled water to prepare a 1mg/mL sample. A reverse phase chromatography column (150 μm i.d.. Times.150mm, packed with Acclaim PepMap RPLC 18,1.9 μm,
) Separating with mobile phase A of 0.1% formic acid water solution and mobile phase B of 0.1% formic acid/80% acetonitrile solution, gradient eluting at 600nL/min flow rate, separating gradient: 0-2min,4-8% of B;2-45min,8-40% by weight B;45-55min,40-60% by weight B;55-56min, 60-95%; 56-66min, 95% B. The mass spectrum ion source type is an electrospray ionization source (ESI), a positive ion scanning mode, a spraying voltage of 2200V and a capillary temperature of 270 ℃. Setting primary mass spectrum parameters: scanning range 100-2000m/z, maximum resolution 70000, and automatic gain parameter 3000000. Setting secondary mass spectrum parameters: scanning range 50-2000m/z, maximum resolution 17500 and automatic gain parameter 100000.
The ion peak mainly appearing in the F1 fraction, as detected by mass spectrometry, comprised m/z =716.393, and was 1 charge. These main molecular ion peaks were further subjected to secondary mass spectrometry, and the secondary mass spectrum of these main molecular ion peaks is shown in fig. 7. The peptide corresponding to these molecular ion peaks was VVTGVGGQ by database matching and manual calculation.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Claims (10)
1. An active peptide for stimulating the secretion of glucagon-1 peptide, which is characterized in that the active peptide is VVTTGVGGQ, and the amino acid sequence is as follows: val-Val-Thr-Gly-Val-Gly-Gly-Gln.
2. A polynucleotide encoding an active peptide that stimulates secretion of glucagon-1 peptide according to claim 1.
3. The method for producing an active peptide that stimulates the secretion of glucagon-1 according to claim 1, wherein the active peptide is artificially synthesized by genetic engineering, or is directly obtained from barley protein by separation and purification, or is directly produced by chemical synthesis.
4. A method for preparing an enzymatic hydrolysate containing an active peptide that stimulates the secretion of glucagon-1 peptide according to claim 1, comprising the steps of: sequentially carrying out enzymolysis on the barley protein by using pepsin and trypsin to obtain a barley protein enzymolysis product, namely an enzymolysis product containing the active peptide for stimulating the secretion of the glucagon-1 peptide as claimed in claim 1.
5. The method of claim 4, wherein the method of extracting the barley protein from barley comprises the steps of:
grinding barley, defatting, adding into distilled water, adjusting pH to 4-6, and pretreating with cellulase for 0.5-2 hr; then adjusting pH to 10-12 for protein extraction, centrifuging after the protein extraction is finished, taking supernatant, adjusting pH of the supernatant to 4.4-4.6, standing, centrifuging, and washing with water; and finally drying to obtain the barley protein.
6. The method according to claim 4, wherein the mass ratio of pepsin or trypsin to barley protein is 1:10-100;
the enzymolysis condition of the pepsin or trypsin is enzymolysis for 1-5h at 37 ℃.
7. The method of claim 4, wherein the step of obtaining the enzymatic hydrolysate of barley protein further comprises the steps of:
separating the barley protein enzymolysis product by using a Toyopearl HW-40F size exclusion chromatographic column, eluting and carrying out chromatographic purification at a certain flow rate by using deionized water as an eluent, and collecting different components; then detecting the influence of different components on the secretion of GLP-1 of enteroendocrine cells, selecting the component which stimulates the GLP-1 to secrete the highest activity as a target component, namely an enzymolysis product containing the active peptide which stimulates the secretion of the glucagon-like peptide-1.
8. An enzymatic hydrolysate containing the active peptide of claim 1 that stimulates secretion of glucagon-1 peptide, which is produced by the production method according to any one of claims 4 to 7.
9. Use of the active peptide for stimulating the secretion of glucagon-1 according to claim 1, or of an enzymatic hydrolysate containing the active peptide for stimulating the secretion of glucagon-1 according to claim 1, for the preparation of a product having at least one of the following functions 1) to 3):
1) Stimulation of GLP-1 secretion;
2) Preventing diabetes;
3) Assisting in reducing blood sugar.
10. A product comprising the active peptide for stimulating the secretion of glucagon-1 according to claim 1 or an enzymatic hydrolysate containing the active peptide for stimulating the secretion of glucagon-1 according to claim 1, wherein the product has at least one of the following functions 1) to 3):
1) Stimulation of GLP-1 secretion;
2) Preventing diabetes;
3) Assisting in reducing blood sugar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210735399.2A CN115353554A (en) | 2022-06-27 | 2022-06-27 | Active peptide for stimulating pancreatic hyperglycemia peptide-1 secretion and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210735399.2A CN115353554A (en) | 2022-06-27 | 2022-06-27 | Active peptide for stimulating pancreatic hyperglycemia peptide-1 secretion and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115353554A true CN115353554A (en) | 2022-11-18 |
Family
ID=84030347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210735399.2A Pending CN115353554A (en) | 2022-06-27 | 2022-06-27 | Active peptide for stimulating pancreatic hyperglycemia peptide-1 secretion and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115353554A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1817904A (en) * | 2005-11-21 | 2006-08-16 | 大连帝恩生物工程有限公司 | Gerobriecin pancrease glucagon peptidel (SGLP-1), its preparation and use |
| WO2018159546A1 (en) * | 2017-03-03 | 2018-09-07 | 森永乳業株式会社 | Glp-1 secretagogue and composition |
-
2022
- 2022-06-27 CN CN202210735399.2A patent/CN115353554A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1817904A (en) * | 2005-11-21 | 2006-08-16 | 大连帝恩生物工程有限公司 | Gerobriecin pancrease glucagon peptidel (SGLP-1), its preparation and use |
| WO2018159546A1 (en) * | 2017-03-03 | 2018-09-07 | 森永乳業株式会社 | Glp-1 secretagogue and composition |
Non-Patent Citations (2)
| Title |
|---|
| ZHONGTIAN YIN等: "Identification of peptides in Qingke baijiu and evaluation of its angiotensin converting enzyme (ACE) inhibitory activity and stability", 《FOOD CHEMISTRY》, vol. 395, pages 1 - 8 * |
| 李洪昌等: "GLP-1治疗2型糖尿病患者的临床疗效分析", 《现代诊断与治疗》, vol. 33, no. 01, pages 63 - 66 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109293740B (en) | Oyster-derived ACE (angiotensin converting enzyme) inhibitory and antitumor active peptide | |
| CN115353553B (en) | CCK secretion-promoting peptide targeting calcium sensitive receptor and preparation method and application thereof | |
| CN110845575B (en) | Polypeptide and application thereof as well as DPP-IV inhibitor or hypoglycemic drug | |
| CN111870659A (en) | Application of enzymolysis cereal bran extract in preparation of DPP-4 inhibitor | |
| CN116143869A (en) | Highland barley source active oligopeptide and preparation method and application thereof | |
| CN113845567B (en) | Tuna roe dipeptidyl peptidase IV inhibition oligopeptide | |
| CN115353554A (en) | Active peptide for stimulating pancreatic hyperglycemia peptide-1 secretion and preparation method and application thereof | |
| CN115353551B (en) | Oat-derived GLP-1 secretion-promoting oligopeptide and preparation method and application thereof | |
| CN114107418B (en) | Preparation method of ginseng polypeptide | |
| CN113845565B (en) | Lumbricus bioactive small peptide, and preparation method and application thereof | |
| CN115536731A (en) | Preparation method of high-activity mung bean albumin glycopeptide-lowering | |
| CN113087773B (en) | Yak bone peptide with blood sugar reducing and antioxidant functions and preparation method thereof | |
| CN115353549A (en) | Small peptide for promoting intestinal hormone secretion and preparation method and application thereof | |
| CN110776557A (en) | Polypeptide and application thereof, and DPP-IV inhibitor or hypoglycemic drug or health product | |
| CN108948213A (en) | Long-actingization oxyntomodulin (OXM) hybrid peptide, preparation method and its purposes as drug | |
| CN101280012B (en) | Exendin-4 active isomer and application thereof | |
| CN110256580B (en) | Application of plant produced oral dolabrin and nattokinase hypoglycemic capsule | |
| CN115124606A (en) | Oligopeptide containing amino acid structure PQQP and preparation method and application thereof | |
| CN107823247B (en) | Application of ethanol extract of taro tuber in reducing lipid deposition of liver cell | |
| CN116082451A (en) | Buckwheat-source cholecystokinin secretion peptide and preparation method and application thereof | |
| CN115010785B (en) | Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof | |
| CN113173970B (en) | Walnut meal anti-inflammatory peptide FPL and application thereof | |
| CN114213516B (en) | Active peptide derived from radix codonopsis pilosulae for promoting lactation and resisting breast tumor, and preparation method and application thereof | |
| WO2011068150A1 (en) | Glucagon-like peptide-1 secretion enhancer | |
| CN112794881B (en) | Anti-liver cancer tridecapeptide NKSGTYSNDDLSH and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |